Leucine-rich α-2-glycoprotein 1 as a promising biomarker and therapeutic target in sepsis: A review.

Sepsis is primarily characterized by a dysregulated host immune response. Identifying specific biomarkers and potential therapeutic targets has become a critical focus and key challenge in current research. Serum leucine-rich α-2-glycoprotein 1 (LRG1) is significantly elevated in sepsis. We aim to elucidate the potential roles of LRG1 in sepsis and its associated organ dysfunction as a specific biomarker for early diagnosis, prognosis assessment, or as an intervention target. This review summarizes the underlying mechanisms by which LRG1 contributes to the pathogenesis and progression of sepsis, particularly through its involvement in inflammation regulation, vascular function, and cell survival. Additionally, it consolidates current knowledge on LRG1 in sepsis, highlights its clinical application potential, and provides new support for precise diagnosis, prognostic evaluation, and targeted therapy. In conclusion, LRG1 emerges as a promising biomarker and therapeutic target for sepsis, playing a crucial role throughout the disease's onset, progression, and prognosis. This review offers new perspectives on LRG1 research and its application in sepsis.